CN1237975C - Application of general saponin of gen-seng fruit in the preparation process of myocarditis treating medicine - Google Patents
Application of general saponin of gen-seng fruit in the preparation process of myocarditis treating medicine Download PDFInfo
- Publication number
- CN1237975C CN1237975C CN 200310115864 CN200310115864A CN1237975C CN 1237975 C CN1237975 C CN 1237975C CN 200310115864 CN200310115864 CN 200310115864 CN 200310115864 A CN200310115864 A CN 200310115864A CN 1237975 C CN1237975 C CN 1237975C
- Authority
- CN
- China
- Prior art keywords
- medicine
- myocarditis
- panacis quinquefolii
- total saponins
- myocardium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to an application of a general saponin of American genseng fruit to the preparation of myocarditis treating medicine, which belongs to the field of the medicinal applications of the effective ingredients of traditional Chinese medicine. The present invention has the purpose of applying the general saponin of American genseng fruit to the preparation of myocarditis treating medicine. The prepared medicine can not only improve myocardial metabolism, nourish the myocardium, protect heart cells and increase the disease resistance of the myocardium, but also directly kill viruses, relieve the damage of viruses to the myocardium, and the side effect of western medicine applied for a long term to a human body, and realize the acting effect of combining virus resistance and integral regulation, so the medicine becomes ideal myocarditis treating medicine. A medicinal composition containing the general saponins of American genseng fruit can also be prepared.
Description
Technical field
The medical usage field of pharmaceutically active ingredient in the invention belongs to.
Background technology
Myocarditis is meant myocardium limitation or diffuse acute or chronic inflammatory disease pathological changes, can be divided into infectious and non-infectious two big classes.Infectious myocarditis can be caused that non-infectious myocarditis then comprises allergy or allergy myocarditis by virus, antibacterial, spirillum, rickettsia, mycete, protozoon, anthelmintic, as myocarditis of rheumatism and chemical factors or drug-induced etc.Myocarditic symptom weight differs, and varying degree is in a bad way.But the lighter's no conscious sympton; Severe patient can show as sudden death, severe arrhythmia, cardiogenic shock or heart failure, causes acute stage death; Also can show as various arrhythmia, pericarditis or acute myocardial infarction etc.Viral myocarditis is the class myocarditis the most common clinically, that number of the infected is maximum, has popularity, risen more than 10 times than sickness rate before 10 years now, become the modal cardiomyopathy of China, pilosity be born among the crowd viral infection popular in, have 5% patient cause viral myocarditis approximately on the virus infected flow departure date.In recent years, the understanding of viral myocarditis is constantly deepened.Can cause that myocarditic virus is a lot, as: Coxsackie virus, adenovirus, influenza virus or the like, wherein the myocarditis that causes with change of coxsackie b virus is especially seen at most, responsive especially to this virus performance because of cardiac muscle, myocardium has special affinity to this virus.After the patient infection Coxsackie virus, 5% the heart that involves is arranged approximately.Focal necrosis all can take place in heart myocardial cell everywhere; With inflammatory cell infiltration, mainly be mononuclear cell in the necrosis region, neutrophilic granulocyte is also arranged sometimes, inflammatory cell reaction sometimes is not obvious.Necrosis region finally replaces for fibrosis, and the clinical manifestation of children virus myocarditis is grown up serious.Viral myocarditis does not have specific treatment so far, and modern medicine generally all is to adopt to suit the medicine to the illness and supporting treatment.Be mainly and alleviate the heart burden, take a good rest and nutrition; Simultaneously carry out symptomatic treatment at symptoms such as the heart failure that occurs, arrhythmia, and cardiac nutrition, the myocardial metabolism of improving, adrenocortical hormone used sometimes.After the increased in acute viral myocarditis, usually need convalescent treatment for a long time, half a year at least, have in addition 1-2, or longer time.Recent study is found, utilizes combination of Chinese and Western medicine method treatment viral myocarditis to receive gratifying effect.Therefore, Chinese medicine is for the improvement of viral myocarditis at symptom control, cardiac function, and the recovery of cardiac muscle and the adjusting aspect of whole machine body function have obtained the approval of extensive patients.
Radix Panacis Quinquefolii (Pana * quinquefolium Linn.) is the araliaceae ginseng plant.The Fructus Panacis Quinquefolii total saponins is a main effective ingredient in the Radix Panacis Quinquefolii fruit, has multiple physiologically active.It is to be raw material in fact with Fructus Panacis Quinquefolii, crosses D type macroporous resin column by decocting liquid, and the ethanol elution with 30-95% obtains again, wherein contains R
0, R
B1, R
B2, Rc, Rd, Re, R
G1, R
G2Etc. plurality of active ingredients.
Summary of the invention
The purpose of this invention is used the myocarditic medicine of Fructus Panacis Quinquefolii total saponins preparation treatment exactly, the medicine of making can not only improve myocardial metabolism, cardiac nutrition, protection heart cell, improve the resistance against diseases of cardiac muscle, and energy direct killing virus, alleviate virus to induced myocardial injury, play antiviral and the integrally-regulated action effect that combines; Alleviate the side effect that the Western medicine prolonged application produces human body, make it become the ideal myocarditic medicine that is used for the treatment of, also can be made into the pharmaceutical composition that contains the Fructus Panacis Quinquefolii total saponins, this pharmaceutical composition can be one or more active component natural or chemosynthesis, also can be the pharmaceutical composition that one or more Chinese crude drugs or its active component and Fructus Panacis Quinquefolii total saponins are formed.
When the present invention was used for the myocarditic medicine of preparation treatment, its oral or non-oral administration all was safe.Under oral situation, it can be any conventionally form administration, as powder, granule, tablet, capsule, pill, drop pill, soft capsule, leafing agent, oral liquid, suspension, syrup, buccal tablets, spray or aerosol etc.; When the non-oral administration of this medicine, can adopt any conventionally form, as suppository, injection (intravenous injection, intramuscular injection), ointment, inhalant etc.
It is to be made of effective site or the plurality of active ingredients monomer excipient with solid or liquid that the present invention prepares the myocarditic medicine of treatment, solid used herein or liquid excipient are well known in the art, lift several object lessons below, the excipient of solid preparation has lactose, starch, paste essence, calcium carbonate, synthetic or puritan filler aluminum, magnesium chloride, magnesium stearate, sodium bicarbonate, dry yeast etc.; The excipient of liquid preparation has water, glycerol, propylene glycol, simple syrup, ethanol, ethylene glycol, Polyethylene Glycol, Sorbitol etc.; The excipient of ointment can use fatty oil, agnolin, vaseline, glycerol, Cera Flava, wood are cured, liquid paraffin, resin, advanced wax etc. are combined into water-repelling agent or hydrophilizing agent.
The dosage of active substance can be according to the mode of taking, patient's age and body weight and be in a bad way degree and other similar factor and change, and oral dose is: 20-1000mg/ people, take for three times every day; The injection consumption is 10-1000mg/ people, once a day.
Its therapeutic effect is by the inhibitory action of Fructus Panacis Quinquefolii total saponins to Coxsackie virus, alleviate arrhythmia, increase anti-cardiomyopathy ability, improve that blood circulation, protecting myocardial cell are avoided damaging etc. and be used for realizing.Dosage is 7.5-140mg/kg, successive administration 5-10 days.
The specific embodiment
Experimental example 1: to the pathological changes caused by virus protective effect
(1) experiment material
Medicine: Fructus Panacis Quinquefolii total saponins, positive control drug are the Radix Astragali.
Cell strain: Hela (cervical cancer cell)
Strain: Coxsackie B virus
3(CVB
3) strain, Coxsackie B virus
4(CVB
4) strain, coxsackie virus A 16 (CVA16), enterovirus E71 strain.
(2) test method and result
On cell, add 10 respectively
-1-10
-64 kinds of viral liquid of variable concentrations, flush away virus liquid adds nontoxic boundary medicinal liquid behind the absorption 1h, and each viral dilution degree respectively adds 3 multiple holes, establishes virus control, cell contrast, positive drug matched group simultaneously.Put 37 ℃ of CO
2Cultivate in the incubator, observe pathological changes every day under inverted microscope, and 4d writes down each hole pathological changes situation continuously.The results are shown in Table 1.
Table 1 pair pathological changes caused by virus effect
Strain Radix Astragali Fructus Panacis Quinquefolii total saponins cell contrast virus control
6.25g/L 1.562g/L
CVA16 ± ± - ++++
Enterovirus E71+--++ ++
CVB
3 ± + - ++++
CVB
4 + ± - ++++
Annotate :-acellular pathological changes shown; ± be shown with and delay cytopathic effect; + show the cytopathy below 1/4; ++ the cell that shows 1/4-1/2 has pathological changes; +++show, the cell of 1/2-3/4 had pathological changes; ++ ++ show that the cell more than 3/4 has pathological changes.
The result shows in the table 1, and the Fructus Panacis Quinquefolii total saponins can the obvious suppression Coxsackie B virus
4And coxsackie virus A 16, to Coxsackie B virus
3Effect slightly a little less than, to enterovirus E71 unrestraint effect.
Experimental example 2: to the influence of mice viral myocarditis
(1) test material
Animal: the Swiss mice, male and female half and half, in age in 3-4 week, 16-18g is provided by the Bethune of Jilin University medical board Experimental Animal Center.
Medicine: Fructus Panacis Quinquefolii total saponins, positive control drug are the Radix Astragali.
(2) test method and result
Inoculation contains 10 through the abdominal cavity with mice
4TCID
50CVB
3Liquid 0.2ml, behind the 1h, gastric infusion, two weeks of successive administration.The virus of model control group mouse inoculation same dose irritates stomach, continuous two weeks for every day the normal saline of same dose.After the last administration, pluck eyeball and get blood, separation of serum is measured myocardium three enzyme glutamic oxaloacetic transaminase, GOTs (AST), creatine phosphokinase (CK), lactic acid dehydrogenase (LDH).The results are shown in Table 2.
The influence of table 2 pair mice viral myocarditis cardiac muscle three enzymes (X ± s)
Group dosage animal AST (U/L) CK (U/L) LDH (U/L)
Virus control 10 524.09 ± 132.76 3375.8 ± 1691.54 2486.14 ± 188.83
Normal control 10 213.47 ± 59.16 936.75 ± 552.34 1792.35 ± 172.75
The total 200mg/kg 10 303.85 ± 49.79 of Fructus Panacis Quinquefolii
*824.02 ± 322.27
*1948.01 ± 114.37
*
Saponin 100mg/kg 10 216.18 ± 43.16
*258.18 ± 149.21
*1772.01 ± 131.20
*
50mg/kg 10 337.58±90.74
* 831.21±469.74
** 2061.68±122.64
*
Radix Astragali 13g/kg 10 284.73 ± 145.28 664.49 ± 592.32
*1782.03 ± 180.20
Annotate: with virus control group ratio,
*P＜0.05,
*P＜0.01
The result shows in the table 2, and the Fructus Panacis Quinquefolii total saponins can significantly reduce myocardium three enzymes in the myocarditis animal pattern blood, has the effect of treatment viral myocarditis.
Experimental example 3: barium chloride is caused the influence of rat ventricular
(1) test material
Medicine: Fructus Panacis Quinquefolii total saponins; The test comfortable cellulose capsule of positive drug, lot number: 941102.Provide by Jilin Province Jian Pharmaceutical Factory.Barium chloride is produced by Kaiyuan chemical reagent factory.
Animal: the wistar rat, body weight 200-250g is available from Jilin Prov. Inst. of Chinese Medicine and Chinese Medical Science animal housing.
(2) test method and result
Get 45 rats, be divided into five groups at random: model group, comfortable cellulose capsule 140mg/kg dosed administration group, Fructus Panacis Quinquefolii total saponins 140,70,35mg/kg dosage group.Every day gastric infusion once, successive administration five days after the last administration 1 hour, in rats by intraperitoneal injection chloral hydrate 300mg/kg anesthesia, is measured normal II lead electrocardiogram.Sublingual vein injection barium chloride 4mg/kg observes electrocardiogram and changes then.Write down that electrocardiogram recovers normal number of animals and arrhythmia persistent period in 20 minutes.The results are shown in Table 3.
Table 3 pair barium chloride causes the influence of rat ventricular
When electrocardiogram recovers arrhythmia and continues in the group number of animals 30 minutes
(only) normal percentage rate (%) (X
2) between (min) (X ± s)
Model control group 9 11.1 27.2 ± 8.33
Comfortable cellulose capsule 140mg/kg 9 44.4 22.2 ± 10.64
Radix Panacis Quinquefolii saponin 140mg/kg 9 66.7
*17.0 ± 11.22
*
70mg/kg 9 33.3 24.4±9.82
35mg/kg 9 33.3 26.7±6.61
Annotate: with the model control group ratio,
*P＜0.05
The result shows, tachycardia appears behind the rat intravenous injection barium chloride immediately, arrhythmia electrocardiograms such as ventricular premature contraction, the animal of taking the Fructus Panacis Quinquefolii total saponins can make the arrhythmia symptom be eased, recovering normal number of animals in 30 minutes obviously increases, and has shortened the ARR persistent period.
Experimental example 4: isoproterenol is caused the influence of rat heart muscle ischemia
(1) test material
Animal: the wistar rat, body weight 200-250g is available from Jilin Prov. Inst. of Chinese Medicine and Chinese Medical Science animal housing.
Medicine; The Fructus Panacis Quinquefolii total saponins; SHENGMAI ZHUSHEYE is produced lot number: 970403 by Pharmacuetical Plant of Huaxi Medical Univ..Isoprenaline (Iso) injection: produce lot number: 951002 by Shanghai Hefeng Pharmaceutical Co., Ltd..
(2) test method and result
Get 58 rats, be divided into six groups at random: blank group, ischemia model group, SHENGMAI ZHUSHEYE 4.5ml/kg dosed administration group, Fructus Panacis Quinquefolii total saponins 20,10, three dosage groups of 5mg/kg.Once a day, the continuous intravenous injection administration is three days.After administration every day 30 minutes, except that the blank group, the equal subcutaneous injection Iso of all the other animals 8mg/kg was administered once after 24 hours again.Preceding 30 minutes of last administration is Iso 2mg/kg of subcutaneous injection again, animal is anaesthetized with chloral hydrate 300mg/kg in 15 minutes after the last administration.The abdomen venous blood collection, separation of serum is measured CK, AST, LDH activity.The results are shown in Table 4.
Table 4 pair isoproterenol causes the influence (X ± s) of rat heart muscle ischemic myocardium three enzymes
Group number of animals AST CK LDH
(only) (U/L) (U/L) (U/L)
Blank group 8 144.6 ± 42.49 3532.0 ± 403.40 573.4 ± 253.57
Model group 10 208.4 ± 101.20 5460.9 ± 1870.24
*863.4 ± 273.27
*
SHENGMAI ZHUSHEYE 10 42.9 ± 30.45 3950.3 ± 1070.01 559.1 ± 106.03
#
Fructus Panacis Quinquefolii total saponins 20mg/kg 10 116.5 ± 11.64
#3532.9 ± 874.17
#408.9 ± 56.87
###
10mg/kg 10 129.6±25.33
# 4096.1±1117.30 459.4±112.44
##
5mg/kg 10 162.5±55.18 4640.0±1502.42 623.0±185.31
#
Annotate: compare with the blank group:
*P＜0.05,
*P＜0.01,
* *P＜0.001
Compare with model group: #P＜0.05, ##P＜0.01, ###P＜0.001
By the result as seen, serum center flesh three enzymes obviously raise after myocardial ischemia appearred in animal, and particularly CK and LDH are apparently higher than the blank group.Injection Fructus Panacis Quinquefolii total saponins can obviously suppress the rising of CK and AST, reduces the activity of LDH, shows tangible function of resisting myocardial ischemia.
Experimental example 5: to the influence of hemorheological property
(1) test material
Animal: the wistar rat, body weight 200-250g is available from Jilin Prov. Inst. of Chinese Medicine and Chinese Medical Science animal housing.
Medicine: Fructus Panacis Quinquefolii total saponins; XUESAITONG is produced lot number: 980651-12 by Kunming Medicine Stock Co., Ltd.Adrenalin hydrochloride (Adr) injection is produced lot number by Mingxing Pharmaceutical Factory, Guangzhou: 961212-1.
(2) test method and result
Get 53 rats, be divided into six groups at random: blank group, blood stasis model group, XUESAITONG 40mg/kg dosed administration group, Fructus Panacis Quinquefolii total saponins 30,15, three dosage groups of 7.5mg/kg.Every day intraperitoneal injection once, continuous four days.0.5h is except that the blank group after the administration in first day, and the Adr 0.1ml/ of the equal subcutaneous injection 0.1% of all the other animals only behind the 0.5h places animal 1.5 ℃ of water ice bath 5min, repeat once after 24 hours, every 24 hours, 0.5h injected Adr again one time after the administration in promptly the 3rd day, but does not carry out ice bath again.0.5h,, puts and measures whole blood contrast viscosity (the high value of cutting, the low value of cutting), plasma viscosity on the blood plasma viscometer in the abdomen venous blood collection Animal Anesthesia in animal lumbar injection pentobarbital sodium 35mg/kg after the last administration.The results are shown in Table 5.
Table 5 injection Fructus Panacis Quinquefolii total saponins is to the influence of blood stasis rat blood rheological characteristic (X ± s)
| Group | Number of animals (only) | Whole blood contrast viscosity (S) | Plasma viscosity (S) | ||
| The high value of cutting | The low value of cutting | ||||
| Blank group blood stasis model group XUESAITONG American ginseng total saponins | 57.0mg/kg 30mg/kg 15mg/kg 7.5mg/kg | 8 9 9 9 9 9 | 4.80±0.694 7.46±1.681*** 5.57±1.332# 5.55±1.108# 6.90±1.710 7.25±1.234 | 6.24±1.142 4.91±6.74** 8.73±3.036 9.13±3.335# 10.82±3.683 12.50±3.700 | 1.61±0.073 1.87±0.326* 1.76±0.134 1.76±0.011 1.72±0.072 1.86±0.368 |
Annotate: compare with the blank group:
*P＜0.05,
*P＜0.01,
* *P＜0.001
Compare with the blood stasis model group: #P＜0.05,
By table 5 result as seen, after the blood stasis symptom appears in animal, show as blood viscosity and increase, hemorheology index generation abnormal change.And behind the animal injection Fructus Panacis Quinquefolii total saponins, whole blood contrast viscosity reduces, and blood viscosity is improved.
Experimental example 6: toxicity
(1) acute toxicity fails to measure the LD of mouse stomach administration because of being limited to Fructus Panacis Quinquefolii total saponins administration volume and administration concentration
50, and measure one in a few days the maximum dosage-feeding of gastric infusion be 30g/kg.The Fructus Panacis Quinquefolii total saponins is given the LD of mouse mainline
50Be its credible 141.03-157.74mg/kg that is limited to of 95% of 149.38mg/kg.
(2) long term toxicity Fructus Panacis Quinquefolii total saponins is given rat oral gavage with 1.5g-0.75g/kg dosage, and with 2.0,1.0g/kg dosage gives dog oral, continuous 60 days, hematology and blood biochemical were learned every check result and all found no abnormal response.Respectively organize data between administration group and the blank group there are no significant difference; Its main organs is not seen drug-induced tangible pathological change yet.
The effect that The above results proof Fructus Panacis Quinquefolii total saponins has multiple viruses such as tangible anti-Coxsackie virus, the Fructus Panacis Quinquefolii total saponins also can suppress ARR generation simultaneously, suppress the generation of myocardial infarction, improve cardiac muscular tissue's pathological changes, improve the effects such as hemorheological property of blood stasis animal.This is for independent application of Fructus Panacis Quinquefolii total saponins and prescription application of treatment viral myocarditis provide theoretical foundation clinically.
Embodiment one:
Capsule: Fructus Panacis Quinquefolii total saponins 180g, starch 20g, mixing, the capsule of packing into No. 2 is made 1000, specification: the 0.2g/ grain.Become human oral, 1/time, three times on the one, one month is a course of treatment.
Embodiment two:
Injection: Fructus Panacis Quinquefolii total saponins 200g, add water 7000ml dissolving, sterilization, drying, sterile sealing is made 1000, and specification: 200mg/ props up.Adult's intravenous drip administration, 1/time, be dissolved in the 250ml normal saline, once-a-day, 15 days is a course of treatment.
Embodiment 3
Tablet: Fructus Panacis Quinquefolii total saponins 180g, starch 20g mixing is made 1000, specification: the 0.2g/ sheet; Become human oral, 1 slice/time, 5 times on the one, a month course of treatment.
Claims (1)
1, the application of Fructus Panacis Quinquefolii total saponins in the myocarditic medicine of preparation treatment, this Fructus Panacis Quinquefolii total saponins are to be raw material in fact with Fructus Panacis Quinquefolii, cross D type macroporous resin column by decocting liquid, and the ethanol elution with 30-95% obtains again.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310115864 CN1237975C (en) | 2003-12-03 | 2003-12-03 | Application of general saponin of gen-seng fruit in the preparation process of myocarditis treating medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310115864 CN1237975C (en) | 2003-12-03 | 2003-12-03 | Application of general saponin of gen-seng fruit in the preparation process of myocarditis treating medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1546050A CN1546050A (en) | 2004-11-17 |
| CN1237975C true CN1237975C (en) | 2006-01-25 |
Family
ID=34337418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310115864 Expired - Fee Related CN1237975C (en) | 2003-12-03 | 2003-12-03 | Application of general saponin of gen-seng fruit in the preparation process of myocarditis treating medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1237975C (en) |
-
2003
- 2003-12-03 CN CN 200310115864 patent/CN1237975C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1546050A (en) | 2004-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111110824B (en) | Medicinal composition for strengthening body resistance and rescuing lung and application thereof | |
| CN1824177A (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN101822789B (en) | Hypotensor treating essential hypertension | |
| CN102526276A (en) | Anti-hypertension medicinal composition and preparation method for same | |
| CN101406613B (en) | Use of Chinese medicinal composition in preparing medicament for treating vital myocarditis | |
| CN1281212C (en) | General saponin of stem and leaf of American ginseng in Application of preparing medication for treating mycoarditis | |
| CN1237975C (en) | Application of general saponin of gen-seng fruit in the preparation process of myocarditis treating medicine | |
| CN107007614A (en) | The medical usage of cycloastragenol | |
| CN100457140C (en) | Pharmaceutical composition containing lamivudine | |
| CN1692938A (en) | Compound traditional Chinese medicine for improving eyesight and its prepn. method | |
| CN100366259C (en) | Application of general saponin of gen-seng fruit in the preparation process of myocarditis treating medicine | |
| CN1943710A (en) | The application of radix ophioponis in the medicines for treating myocarditis and medicines containing its extracts with active elements | |
| CN101032534A (en) | Method of preparing jiubiying total saponins and the application thereof | |
| CN1857531A (en) | Recipe, preparing process and application of Chinese medicine preparation for treating diabetic retinopathy | |
| CN1718191A (en) | Total secondary ginseng glucoside oral disintegration tablets prepn. method and application thereof | |
| CN105833051B (en) | The pharmaceutical composition of a kind of shield heart dredging collateral and containing its preparation and application | |
| CN1720982A (en) | Sugar decreasing composition of fenugreek seed | |
| CN114272254B (en) | Application of combination of glycyrrhetinic acid and paeoniflorin in treating liver injury and liver fibrosis | |
| CN1307973C (en) | Orally disintegrating tablet for dredging vascular thrombus and its preparation process | |
| CN1552723A (en) | Liaodong oak leaf saponin and its medicinal composition | |
| CN1316992C (en) | Medicine for treating heart brain embulus disease and its preparation method | |
| CN1242801C (en) | Medicinal composition for treating coronary heart disease and angine pectoris | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1660284A (en) | Compound preparation of notoginseng and safflower for treating cardiovascular and cerebrovascular diseases | |
| CN1923260A (en) | Medicine for treating coronary disease of stenocardia type and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060125 Termination date: 20151203 |
|
| EXPY | Termination of patent right or utility model |